Brimonidine

Mechanism-of-action classes: Adrenergic alpha-Agonists; Adrenergic alpha2-Agonists.

• Use relieves redness of the eye due to minor eye irritations

Directions adults and children 5 years of age and over: instill 1 drop in the affected eye(s) every 6-8 hours do not use more than 4 times daily remove contact lenses before use wait at least 10 minutes before re-inserting contact lenses after use if using other ophthalmic products while using this product, wait at least 5 minutes between each product to avoid contamination, do not touch tip of container to any surface replace cap after each use children under 5 years of age: consult a doctor

For external use only Do not use if solution changes color or becomes cloudy Stop use and ask a doctor if you experience eye pain, changes in vision, continued redness or irritation of the eye condition worsens or persists for more than 3 days If pregnant or breast-feeding, ask a health professional before use. Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away.

• Mar 16, 2001NDANDA021262Abbvie
• Aug 19, 2005NDANDA021770Abbvie
• May 22, 2006NDANDA021764Sandoz
• Oct 30, 2007NDANDA021398Abbvie
• Apr 19, 2013NDANDA204251Alcon Labs Inc
• Aug 23, 2013NDANDA204708Galderma Labs Lp
• Dec 22, 2017NDANDA208144Bausch And Lomb Inc
• Apr 19, 2024NDANDA218424Bausch And Lomb Inc

Recent PubMed references pinned to Brimonidine as a MeSH major topic. Citations link to pubmed.ncbi.nlm.nih.gov.

• The Prophylactic Effect of Dexmedetomidine 0.008% Versus Brimonidine 0.2% on IOP Elevation After Nd: YAG Laser Capsulotomy.
  Pharmacology research & perspectives · 2026 · Zakeri P, Akhavanakbari G, Ojaghi H, et al.
  PMID 42192576DOI 10.1002/prp2.70227
• Brimonidine attenuates choroidal thinning and hypoperfusion in guinea pigs with form-deprivation myopia: Involvement of NOS and TGF-β1.
  European journal of pharmacology · 2026 · Zeng F, He H, Luo Y, et al.
  PMID 42105994DOI 10.1016/j.ejphar.2026.178947
• Acute anterior segment biometric effects of brimonidine assessed by swept source OCT supporting its use in managing visual disturbances.
  Scientific reports · 2026 · Limón-Zurita PA, Gulias-Cañizo R, Guerrero-Berger O, et al.
  PMID 41957216DOI 10.1038/s41598-026-47159-5
• Brimonidine Therapy for Protection From Noise-Induced Hearing Loss.
  Aging cell · 2026 · Cai J, Zhang N, Song Y, et al.
  PMID 41953996DOI 10.1111/acel.70481
• Identification of Brimonidine as a Novel Substrate of Organic Cation Transporters OCT2 and MATE1 Expressed in Human Eye.
  Investigative ophthalmology & visual science · 2026 · Kölz C, Neul C, Hofmann U, et al.
  PMID 41925694DOI 10.1167/iovs.67.4.4
• Topical Brimonidine Is Associated With Trabeculectomy Failure in Glaucoma Patients.
  American journal of ophthalmology · 2026 · Yang S, Lin WC, Kokoyan A, et al.
  PMID 41759650DOI 10.1016/j.ajo.2026.02.026
• Fixed Triple-Combination Bimatoprost/Brimonidine/Timolol Versus Separate Administration in Glaucoma: Randomized Clinical Trial.
  Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics · 2026 · Machado LF, Kawamuro M, Bando A, et al.
  PMID 41738452DOI 10.1177/10807683261421428
• Brimonidine Beyond a Single Specialty: Pharmacological Profile, Dermatologic Applications, and Advances in Drug Delivery Systems.
  International journal of molecular sciences · 2026 · Jóźwiak W, Pietrusiewicz M, Piechota-Urbańska M, et al.
  PMID 41683709DOI 10.3390/ijms27031281

The 10 most recently updated of 212 ClinicalTrials.gov registrations naming Brimonidine as an intervention. Registration is not evidence of efficacy or safety — reference crosswalk only.

• A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression
  Recruiting · Phase 2 · Interventional · 100 enrolled · AbbVie
  NCT06365853updated 2026-06-12
• Gastric Ultrasound for Airway Management in Emergency Patients
  Completed · Observational · 43 enrolled · Indonesia University
  NCT07640165updated 2026-06-10
• Strategies to Decentralize Breast Ultrasound in Rwanda
  Not yet recruiting · Interventional · 1,792 enrolled · Brigham and Women's Hospital
  NCT06812208updated 2026-06-02
• A Study Comparing the Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution 0.025% With Sodium Hyaluronate Relative to Lumify in Adult Subjects With Ocular Redness
  Completed · Phase 3 · Interventional · 578 enrolled · Bausch & Lomb Incorporated
  NCT06803654updated 2026-05-28
• Upneeq vs. Lumify Ptosis
  Not yet recruiting · Phase 4 · Interventional · 50 enrolled · Duke University
  NCT07390578updated 2026-05-22
• Phase 3 Safety Study of LNZ100 and LNZ101 for the Treatment of Presbyopia Subjects
  Completed · Phase 3 · Interventional · 362 enrolled · LENZ Therapeutics, Inc
  NCT05753189updated 2026-05-13
• Phase 3 Evaluation of the Safety and Efficacy of LNZ100 & LNZ101 for the Treatment of Presbyopia
  Completed · Phase 3 · Interventional · 469 enrolled · LENZ Therapeutics, Inc
  NCT05656027updated 2026-05-13
• Comparative Study of the Efficacy of Either Krytantek Ofteno PF® or Eliptic Ofteno PF® Plus Gaap Ofteno PF® for POAG or Ocular Hypertension.
  Terminated · Phase 4 · Interventional · 28 enrolled · Laboratorios Sophia S.A de C.V.
  NCT04702789updated 2026-05-07
• Retinal Ganglion Cell Neuroprotection Under Prostaglandin Analogues
  Not yet recruiting · Observational · 1,500 enrolled · Association for Innovation and Biomedical Research on Light and Image
  NCT07074782updated 2026-05-06
• The PASTDUe Nutrition Ecosystem Project (PASTDUe)
  Active not recruiting · Phase 4 · Interventional · 300 enrolled · Duke University
  NCT05127109updated 2026-04-23

Ranked by 2D fingerprint (Tanimoto) similarity over PubChem structures. Structural proximity only — not a claim of therapeutic equivalence.

• ClonidineCentral alpha-2 Adrenergic Agonist91%

Frequently asked questions

How does Brimonidine work?

Mechanism-of-action classes: Adrenergic alpha-Agonists; Adrenergic alpha2-Agonists.

What is Brimonidine used for?

According to FDA labeling, Brimonidine carries indications including: Use relieves redness of the eye due to minor eye irritations. This is a reference summary of labeled uses, not medical advice or a treatment recommendation.

What class of drug is Brimonidine?

Brimonidine is classified as Other dermatologicals, Sympathomimetics in glaucoma therapy, Sympathomimetics used as decongestants, alpha-Adrenergic Agonist, Adrenergic alpha-Agonists, Adrenergic alpha2-Agonists, Decreased Intraocular Fluid Pressure.

What are the brand names for Brimonidine?

Brimonidine is marketed under brand names including Alphagan, Combigan, Lumify, Mirvaso, Simbrinza, Yuvezzi.